Prot #MK-3475-164-02: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma

Project: Research project

Project Details

StatusFinished
Effective start/end date12/16/15 → 12/16/18

Funding

  • Merck Sharp & Dohme Corporation (Prot #MK-3475-164-02)